Corline Biomedical AB (FRA:IZ7) Total Liabilities: €1.44 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IZ7 Corline Biomedical AB FRA:IZ7
43 GF Score
Price €1.55
GF Value €0.45
! 3 Warning Signs
View Full Analysis

What is Corline Biomedical AB Total Liabilities?

Corline Biomedical AB FRA:IZ7 -2.52% 43 Total Liabilities is €1.44 Mil as of Mar. 2026. GuruFocus rates FRA:IZ7 with a GF Score™ of 43/100 and a GF Value™ of €0.45. The stock has 3 warning signs investors should review.

Corline Biomedical AB's Total Liabilities for the quarter that ended in Mar. 2026 was €1.44 Mil.

Corline Biomedical AB's quarterly Total Liabilities declined from Sep. 2025 (€0.46 Mil) to Dec. 2025 (€0.44 Mil) but then increased from Dec. 2025 (€0.44 Mil) to Mar. 2026 (€1.44 Mil).

Corline Biomedical AB's annual Total Liabilities increased from Dec. 2023 (€0.61 Mil) to Dec. 2024 (€0.68 Mil) but then declined from Dec. 2024 (€0.68 Mil) to Dec. 2025 (€0.44 Mil).

Corline Biomedical AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Corline Biomedical AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corline Biomedical AB Total Liabilities Chart

Corline Biomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.65 0.61 0.68 0.44

Corline Biomedical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.52 0.46 0.44 1.44
FRA:IZ7
43GF Score
Corline Biomedical AB FRA:IZ7
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corline Biomedical AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Corline Biomedical AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.443+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.44

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=9.059-8.616
=0.44

Corline Biomedical AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.594+(0+0.848
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.44

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=10.767-9.325
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €1.44 Mil mean?
Corline Biomedical AB (FRA:IZ7) has a Total Liabilities of €1.44 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Corline Biomedical AB and its competitors.
Is Corline Biomedical AB's Total Liabilities too high?
Corline Biomedical AB's current Total Liabilities is €1.44 Mil. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Total Liabilities compare to VRTX and REGN?
Corline Biomedical AB's Total Liabilities of €1.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Corline Biomedical AB and its competitors. Corline Biomedical AB's current Total Liabilities is €1.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current Total Liabilities of €1.44 Mil. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current Total Liabilities is €1.44 Mil. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current Total Liabilities is €1.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.

Key valuation signals for FRA:IZ7:

  • Total Liabilities: €1.44 Mil
  • GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corline Biomedical AB Business Description

Other Exchanges CLBIO:Sweden
Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score

Get the complete analysis for FRA:IZ7

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€0.45
GF Value